Safety and immunogenicity of a novel nanoemulsion mucosal adjuvant W 805EC combined with approved seasonal influenza antigens

Vaccine

Volumn 30, Issue 2, 2012, Pages 307-316

  Stanberry, L R ^a   Simon, J K ^b   Johnson, C ^c   Robinson, P L ^b   Morry, J ^d   Flack, M R ^b   Gracon, S ^b   Myc, A ^d   Hamouda, T ^b   Baker, J R ^b,d  

^a Och Spine at New York Presbyterian Hospitals   (United States)

^b NanoBio Corporation   (United States)

^c Johnson County Clin Trials   (United States)

^d UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

Author keywords

Adjuvant; Clinical trial; Human; Immunogenicity; Inactivated; Influenza; Intranasal; Mucosal; Nanodroplet; Nanoemulsion; Nanoemulsion adjuvant; Nanotechnology; Nasal; Safety; Tolerability; Trivalent; Vaccine; W 805EC

Indexed keywords

ADJUVANT; IMMUNOGLOBULIN A; INFLUENZA VACCINE; UNCLASSIFIED DRUG; VIRUS ANTIGEN; W805EC ADJUVANT;

ADULT; ADVERSE OUTCOME; ANEMIA; ANTIBODY TITER; ANTIGEN SPECIFICITY; ARTICLE; DRUG DOSE ESCALATION; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; IMMUNE RESPONSE; IMMUNOGENICITY; INJECTION SITE PAIN; LABORATORY TEST; MALE; MYALGIA; NANOEMULSION; NAUSEA; NORMAL HUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RHINORRHEA; SEASONAL INFLUENZA; SORE THROAT; VACCINATION; VIRUS STRAIN;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, MUCOSAL; ADULT; ANTIBODIES, VIRAL; ANTIGENS, VIRAL; FEMALE; HEMAGGLUTINATION INHIBITION TESTS; HUMAN EXPERIMENTATION; HUMANS; IMMUNOGLOBULIN A; INFLUENZA VACCINES; MALE; MIDDLE AGED; NASAL MUCOSA;

EID: 84355161937     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.094     Document Type: Article

References (47)

1. Chen K., Cerutti A. Vaccination strategies to promote mucosal antibody responses. Immunity 2010, 33(October (4)):479-491.
2. Brandtzaeg P. Mucosal immunity: induction, dissemination, and effector functions. Scand J Immunol 2009, 70(December (6)):505-515.
3. Cluff C.W., Baldridge J.R., Stover A.G., Evans J.T., Johnson D.A., Lacy M.J., et al. Synthetic toll-like receptor 4 agonists stimulate innate resistance to infectious challenge. Infect Immun 2005, 73(May (5)):3044-3052.
4. Asahi-Ozaki Y., Yoshikawa T., Iwakura Y., Suzuki Y., Tamura S., Kurata T., et al. Secretory IgA antibodies provide cross-protection against infection with different strains of influenza B virus. J Med Virol 2004, 74(October (2)):328-335.
5. Belshe R.B., Gruber W.C., Mendelman P.M., Cho I., Reisinger K., Block S.L., et al. Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. J Pediatr 2000, 136(2):168-175.
6. Johnson P.R., Feldman S., Thompson J.M., Mahoney J.D., Wright P.F. Immunity to influenza A virus infection in young children: a comparison of natural infection, live cold-adapted vaccine, and inactivated vaccine. J Infect Dis 1986, 154(July (1)):121-127.
7. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 1998, 338(20):1405-1412.
8. Atmar R.L., Keitel W.A., Cate T.R., Munoz F.M., Ruben F., Couch R.B. A dose-response evaluation of inactivated influenza vaccine given intranasally and intramuscularly to healthy young adults. Vaccine 2007, 25(July (29)):5367-5373.
9. Greenbaum E., Engelhard D., Levy R., Schlezinger M., Morag A., Zakay-Rones Z. Mucosal (SIgA) and serum (IgG) immunologic responses in young adults following intranasal administration of one or two doses of inactivated, trivalent anti-influenza vaccine. Vaccine 2004, 22(June (20)):2566-2577.
10. Glueck R. Pre-clinical and clinical investigation of the safety of a novel adjuvant for intranasal immunization. Vaccine 2001, 20(Oct 15 (Suppl 1)):S42-S44.
11. Myc A., Kukowska-Latallo J.F., Bielinska A.U., Cao P., Myc P.P., Janczak K., et al. Development of immune response that protects mice from viral pneumonitis after a single intranasal immunization with influenza A virus and nanoemulsion. Vaccine 2003, 21(September (25-26)):3801-3814.
12. Bielinska A.U., Chepurnov A.A., Landers J.J., Janczak K.W., Chepurnova T.S., Luker G.D., et al. A novel, killed-virus nasal vaccinia virus vaccine. Clin Vaccine Immunol 2008, 15(February (2)):348-358.
13. Hamouda T., Chepurnov A., Mank N., Knowlton J., Chepurnova T., Myc A., et al. Efficacy, immunogenicity and stability of a novel intranasal nanoemulsion-adjuvanted influenza vaccine in a murine model. Hum Vaccin 2010, 6(July (7)):1-10.
14. Hamouda T., Sutcliffe J.A., Ciotti S., Baker J.R. Intranasal immunization of ferrets with commercial trivalent influenza vaccines formulated in a nanoemulsion-based adjuvant. Clin Vaccine Immunol 2011, (May).
15. Bielinska A.U., Gerber M., Blanco L.P., Makidon P.E., Janczak K.W., Beer M., et al. Induction of Th17 cellular immunity with a novel nanoemulsion adjuvant. Crit Rev Immunol 2010, 30(2):189-199.
16. Bielinska A.U., Janczak K.W., Landers J.J., Makidon P., Sower L.E., Peterson J.W., et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect Immun 2007, 75(August (8)):4020-4029.
17. Fujimura Y., Takeda M., Ikai H., Haruma K., Akisada T., Harada T., et al. The role of M cells of human nasopharyngeal lymphoid tissue in influenza virus sampling. Virchows Arch 2004, 444(January (1)):36-42.
18. WHO Media Influenza Factsheet N° 211; 2009.
19. Simonsen L. The global impact of influenza on morbidity and mortality. Vaccine 1999, 17(July (SUPPL. 1)):S3-S10.
20. Izurieta H.S., Thompson W.W., Kramarz P., Shay D.K., Davis R.L., DeStefano F., et al. Influenza and the rates of hospitalization for respiratory disease among infants and young children. N Engl J Med 2000, 342(4):232-239.
21. Monto A.S. Epidemiology of influenza. Vaccine 2008, 26(September (SUPPL. 4)):D45-D48.
22. Influenza virus vaccine fluzone package insert 2008, Sanofi Pasteur.
23. World Health Organization Collaborative Center for Influenza. The hemagglutination inhibition test for influenza viruses. Biological Products Division; 1975.
24. de Bernardi di Valserra M., Zanasi A., Ragusa S., Gluck R., Herzog C. An open-label comparison of the immunogenicity and tolerability of intranasal and intramuscular formulations of virosomal influenza vaccine in healthy adults. Clin Ther 2002, 24(January (1)):100-111.
25. Block S.L., Reisinger K.S., Hultquist M., Walker R.E. Comparative immunogenicities of frozen and refrigerated formulations of live attenuated influenza vaccine in healthy subjects. Antimicrob Agents Chemother 2007, 51(November (11)):4001-4008.
26. Langley J.M., Halperin S.A., McNeil S., Smith B., Jones T., Burt D., et al. Safety and immunogenicity of a proteosome-trivalent inactivated influenza vaccine, given nasally to healthy adults. Vaccine 2006, 24(March (10)):1601-1608.
27. Durrer P., Gluck U., Spyr C., Lang A.B., Zurbriggen R., Herzog C., et al. Mucosal antibody response induced with a nasal virosome-based influenza vaccine. Vaccine 2003, 21(October (27-30)):4328-4334.
28. Simonsen L., Kane A., Lloyd J., Zaffran M., Kane M. Unsafe injections in the developing world and transmission of bloodborne pathogens: a review. Bull World Health Org 1999, 77(10):789-800.
29. Sendi P., Locher R., Bucheli B., Battegay M. Intranasal influenza vaccine in a working population. Clin Infect Dis 2004, 38(April (7)):974-980.
30. Needle-free injection technology; 2008, 13 May 2008. Available from: [cited 01.11.10]. http://www.cdc.gov/vaccinesafety/vaxtech/nfit/.
31. Lloyd J. Technologies for vaccine delivery in the 21st century 2000, World Health Organization, Department of Vaccines and Biologicals.
32. Choosing technologies for safe injections; 2005, 13 July 2005. Available from: [cited 01.11.10]. https://apps.who.int/vaccines-access/injection/injection_safety/safe_injections_choosing_technologies.htm.
33. Priority technologies and operational strategies to increase access to immunization; 2008, 23 September 2008.Available from: http://www.gavialliance.org/resources/techprojects2.doc.
34. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350(February (9)):896-903.
35. Renegar K.B., Small P.A. Passive transfer of local immunity to influenza virus infection by IgA antibody. J Immunol 1991, 146(March (6)):1972-1978.
36. Clements M.L., Betts R.F., Tierney E.L., Murphy B.R. Serum and nasal wash antibodies associated with resistance to experimental challenge with influenza A wild-type virus. J Clin Microbiol 1986, 24(July 1):157-160.
37. Simon J.K., Ramirez K., Cuberos L., Campbell J.D., Viret J.F., Munoz A., et al. Mucosal IgA responses in healthy adult volunteers following intranasal spray delivery of a live attenuated measles vaccine. Clin Vaccine Immunol 2011, 18(March (3)):355-361.
38. Beyer W.E., Palache A.M., de Jong J.C., Osterhaus A.D. Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. Vaccine 2002, 20(January (9-10)):1340-1353.
39. Crifo S., Vella S., Filiaci F., Resta S., Rocchi G. Secretory immune response after nasal vaccination with live attenuated influenza viruses. Rhinology 1980, 18(June (2)):87-92.
40. Belshe R.B., Gruber W.C., Mendelman P.M., Mehta H.B., Mahmood K., Reisinger K., et al. Correlates of immune protection induced by live, attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine. J Infect Dis 2000, 181(3):1133-1137.
41. Keitel W.A., Couch R.B., Cate T.R., Hess K.R., Baxter B., Quarles J.M., et al. High doses of purified influenza A virus hemagglutinin significantly augment serum and nasal secretion antibody responses in healthy young adults. J Clin Microbiol 1994, 32(October (10)):2468-2473.
42. Moldoveanu Z., Clements M.L., Prince S.J., Murphy B.R., Mestecky J. Human immune responses to influenza virus vaccines administered by systemic or mucosal routes. Vaccine 1995, 13(August (11)):1006-1012.
43. Boyce T.G., Gruber W.C., Coleman-Dockery S.D., Sannella E.C., Reed G.W., Wolff M., et al. Mucosal immune response to trivalent live attenuated intranasal influenza vaccine in children. Vaccine 1999, 18(August (1-2)):82-88.
44. Treanor J., Nolan C., O'Brien D., Burt D., Lowell G., Linden J., et al. Intranasal administration of a proteosome-influenza vaccine is well-tolerated and induces serum and nasal secretion influenza antibodies in healthy human subjects. Vaccine 2006, 24(January (3)):254-262.
45. Guidance for Industry: Clinical Data Needed to Support the Licensure of seasonal Inactivated Influenza Vaccines. 2007 2010/08/19/[cited; Available from:. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Vaccines/ucm091990.pdf.
46. Buoen C., Holm S., Thomsen M.S. Evaluation of the cohort size in phase I dose escalation trials based on laboratory data. J Clin Pharmacol 2003, 43(May (5)):470-476.
47. Feise R.J. Do multiple outcome measures require p-value adjustment?. BMC Med Res Methodol 2002, 2(June):8.